John C. Byrd

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

John C. Byrd · Blood · 2002 · 1.6K citations

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak et al. · The Lancet · 2020 · 583 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Oncology +8

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

John C. Byrd · Blood · 2002 · 572 citations · Full text

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

John C. Byrd · Blood · 2004 · 401 citations · Full text

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia

Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks et al. · Journal of Clinical Investigation · 2007 · 331 citations · Full text